TABLE 1.
Clinical and treatment characteristics of paediatric patients with lymphoblastic T-cell non-Hodgkin lymphoma (n = 29)
| Characteristic | n (%) | Mean (± SD) |
|---|---|---|
| Median age, yearsa | 11.0 (1.0–18.0) | |
| Gender | ||
| Male | 25 (86.2) | |
| Female | 4 (13.8) | |
| Treatment protocol | ||
| BFM86 | 2 (6.9) | |
| BFM90 | 9 (31.0) | |
| BFM95 | 9 (31.0) | |
| ICBFM02 | 9 (31.0) | |
| MTX dose, mg/m2 | ||
| 2000 | 1 (3.5) | |
| 5000 | 28 (96.5) | |
| Any cycle with delayed MTX clearance | 14 (46.7) | |
| Cmax, μmol/lb | 49.9 (± 31.2) | |
| AUC1, μmol*h/lc | 323.3 (± 250.6) | |
| AUC2, μmol*h/lc | 356.8 (± 215.6) | |
| AUC3, μmol*h/ld | 297.7 (± 202.0) | |
| AUC4, μmol*h/le | 418.4 (± 340.2) | |
| Treatment outcome | ||
| First remission | 21 (72.4) | |
| Eventf | 8 (27.6) |
AUC = area under the time-concentration curve after first (1), second (2), third (3), and fourth (4) application; BFM = Berlin-Frankfurt-Münster; Cmax = maximal MTX plasma concentration; ICBFM = intercontinental Berlin-Frankfurt-Münster; MTX = methotrexate; SD = standard deviation
a
Age is presented as median (range);
b
Data missing for 2 (6.9%) patients;
c
Data missing for 8 (27.6%) patients;
d
Data missing for 11 (37.9%) patients;
e
Data missing for 10 (34.5%) patients;
f
Event was defined as disease relapse at any site, death from any cause, or the occurrence of second malignant neoplasm